# Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

> **NCT00367601** · PHASE2 · COMPLETED · sponsor: **Nasser Hanna, M.D.** · enrollment: 25 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00367601
- **Lead sponsor:** Nasser Hanna, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-04
- **Final completion:** 2008-12
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-02-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00367601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00367601, "Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00367601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*